{"filing":{"accession_number":"0001171843-26-006011","cik":"0001760854","ticker":"NNBXF","company_name":"Nanobiotix S.A.","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"f6k_091326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1760854/000117184326006011/f6k_091326.htm"},"events":[{"id":33058,"run_id":30385,"accession_number":"0001171843-26-006011","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"This is a press release announcing completed Phase 1 clinical trial results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer. The disclosure reports safety and efficacy data (79% one-year locoregional control, 61% one-year LPFS, 70% one-year OS) with no dose-limiting toxicities, presented at IASLC 2026 World Conference. While technically a clinical milestone rather than financial earnings, this is a material event disclosure of significant clinical progress for a late-stage biotech company's lead product candidate, warranting classification as a material clinical results announcement analogous to an earnings release in the biotech context.","company_name":"Nanobiotix S.A.","ticker":"NNBXF","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36390,"accession_number":"0001171843-26-006011","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing completed Phase 1 clinical trial results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer. The disclosure reports safety and efficacy data (79% one-year locoregional control, 61% one-year LPFS, 70% one-year OS) with no dose-limiting toxicities, presented at IASLC 2026 World Conference. While technically a clinical milestone rather than financial earnings, this is a material event disclosure of significant clinical progress for a late-stage biotech company's lead product candidate, warranting classification as a material clinical results announcement analogous to an earnings release in the biotech context.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:04:50.340856+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36390,"accession_number":"0001171843-26-006011","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"This is a press release announcing completed Phase 1 clinical trial results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer. The disclosure reports safety and efficacy data (79% one-year locoregional control, 61% one-year LPFS, 70% one-year OS) with no dose-limiting toxicities, presented at IASLC 2026 World Conference. While technically a clinical milestone rather than financial earnings, this is a material event disclosure of significant clinical progress for a late-stage biotech company's lead product candidate, warranting classification as a material clinical results announcement analogous to an earnings release in the biotech context.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:04:50.340856+00:00","company_name":"Nanobiotix S.A.","ticker":"NNBXF","filing_date":"2026-09-14"}]}